U.S. market Closed. Opens in 3 hours 32 minutes

ZYNE | Zynerba Pharmaceuticals, Inc. Stock Financials Income Statements Annual

(Stock Exchange: NASDAQ)
*Sign In to persist settings
Financial Year End2022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-31
RevenueN/AN/AN/AN/A86.00KN/A7.25K278.90K810.01K943.90K
Cost of RevenueN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
Gross ProfitN/AN/AN/AN/A86.00KN/AN/A278.90K810.01K943.90K
Operating Expenses35.25M36.77M52.06M34.32M40.48M32.82M23.21M12.81M6.48M1.58M
Selling, General & Admin14.15M15.35M16.41M13.94M13.24M10.02M6.43M5.36M4.08M444.30K
Research & Development21.10M21.42M35.65M20.38M27.25M22.81M16.78M7.45M2.40M1.13M
Other Operating ExpensesN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
Operating Income-35.25M-36.77M-52.06M-34.32M-40.40M-32.82M-23.21M-12.53M-5.67M-634.44K
Other Expenses / Income215.73K-538.63K725.71K1.38M-474.67K810.71K-208.42K7.35K-1.84K-2.35K
Before Tax Income-35.04M-37.31M-51.34M-32.94M-39.91M-32.01M-23.42M-12.52M-5.67M-636.79K
Income Tax Expenses-215.73K291.49K-932.75K-1.51M486.65KN/A-27.54K27.54KN/AN/A
Net Income-34.82M-37.60M-50.40M-31.43M-39.91M-32.01M-23.39M-12.55M-5.67M-636.79K
Interest Expenses-215.73KN/AN/AN/AN/AN/AN/AN/AN/AN/A
Basic Shares Outstanding42.66M39.26M27.02M22.00M15.31M12.91M9.07M4.46M2.22M5.73M
Diluted Shares Outstanding42.66M39.26M27.02M22.00M15.31M12.91M9.07M4.46M2.22M5.73M
EBITDA-34.62M-36.21M-52.54M-34.17M-39.92M-31.92M-23.34M-12.50M-5.64M-587.40K
EBITDA Margin0.00%0.00%0.00%0.00%-46,422.28%0.00%-321,941.37%-4,481.10%-696.60%-62.23%
EBIT-35.25M-37.31M-51.34M-32.94M-39.42M-32.01M-23.42M-12.52M-5.67M-636.79K
EBIT Margin0.00%0.00%0.00%0.00%-45,842.47%0.00%-322,980.00%-4,490.43%-699.94%-67.46%
Financial Year End2022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-31
An error has occurred. This application may no longer respond until reloaded. Reload 🗙